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A bs tr ac t
Background
Colonoscopy and fecal immunochemical testing (FIT) are accepted strategies for 
colorectal-cancer screening in the average-risk population.
Methods
In this randomized, controlled trial involving asymptomatic adults 50 to 69 years of 
age, we compared one-time colonoscopy in 26,703 subjects with FIT every 2 years in 
26,599 subjects. The primary outcome was the rate of death from colorectal cancer 
at 10 years. This interim report describes rates of participation, diagnostic findings, and 
occurrence of major complications at completion of the baseline screening. Study 
outcomes were analyzed in both intention-to-screen and as-screened populations.
Results
The rate of participation was higher in the FIT group than in the colonoscopy group 
(34.2% vs. 24.6%, P<0.001). Colorectal cancer was found in 30 subjects (0.1%) in the 
colonoscopy group and 33 subjects (0.1%) in the FIT group (odds ratio, 0.99; 95% 
confidence interval [CI], 0.61 to 1.64; P = 0.99). Advanced adenomas were detected 
in 514 subjects (1.9%) in the colonoscopy group and 231 subjects (0.9%) in the FIT 
group (odds ratio, 2.30; 95% CI, 1.97 to 2.69; P<0.001), and nonadvanced adenomas 
were detected in 1109 subjects (4.2%) in the colonoscopy group and 119 subjects 
(0.4%) in the FIT group (odds ratio, 9.80; 95% CI, 8.10 to 11.85; P<0.001).
Conclusions
Subjects in the FIT group were more likely to participate in screening than were those 
in the colonoscopy group. On the baseline screening examination, the numbers of 
subjects in whom colorectal cancer was detected were similar in the two study 
groups, but more adenomas were identified in the colonoscopy group. (Funded by 
Instituto de Salud Carlos III and others; ClinicalTrials.gov number, NCT00906997.)
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Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths.1 
Several studies have shown that colorectal-cancer 
screening is effective2-5 and cost-effective6 in the 
average-risk population.
Recommended strategies for colorectal-cancer 
screening fall into two broad categories: stool tests 
(occult blood and exfoliated DNA tests) and struc-
tural examinations (flexible sigmoidoscopy, colo-
noscopy, and computed tomographic colonogra-
phy). Stool tests primarily detect cancer, and 
structural examinations detect both cancer and 
premalignant lesions.2 Stool tests for occult blood 
(guaiac testing and fecal immunochemical test-
ing [FIT]) are predominantly used in Europe and 
Australia, whereas colonoscopy is the predomi-
nant screening method in the United States.
Colonoscopy is considered the most accurate 
test for early detection and prevention of colorectal 
cancer. Although data from randomized studies 
evaluating the effect of colonoscopy on the rate of 
death from colorectal cancer are lacking, the pro-
cedure is recommended as a first-line screening 
test on the basis of indirect data and observational 
studies. Population-based case–control studies 
have suggested that colonoscopy markedly reduces 
the risk of colorectal cancer7,8 and death.9 Recent 
evidence suggests that patients with no abnor-
malities on a previous colonoscopy have a mark-
edly reduced risk of colorectal cancer.8,10,11 In a 
cohort of average-risk subjects, the use of screen-
ing colonoscopy was associated with a reduction in 
the incidence of colorectal cancer of 67% and a 
reduction in the rate of death of 65%.12 Cohort 
studies involving patients with adenomas have sug-
gested that polypectomy can prevent approximate-
ly 80% of colorectal cancers.13,14
Comparative studies have shown that the semi-
quantitative FIT is more accurate than the guaiac 
test for the detection of colorectal cancer and ad-
vanced adenomas,15-19 and this new test is now 
recommended as the first-choice fecal occult blood 
test in colorectal-cancer screening. Although FIT 
is less effective for neoplastic detection than colo-
noscopy or sigmoidoscopy, evidence suggests that 
it may be better accepted,20,21 and higher accep-
tance may counteract its lower detection capacity. 
It has been suggested that FIT may be more effec-
tive and less costly than other screening strate-
gies. We conducted a randomized, controlled trial 
to compare semiquantitative FIT with colonos-
copy. We hypothesized that FIT screening every 
2 years would be noninferior to one-time colonosco-
py with respect to a reduction in mortality related 
to colorectal cancer among average-risk subjects. 
This interim report describes rates of participation, 
diagnostic findings, and the occurrence of major 
complications at the completion of the baseline 
screening.
Me thods
Study Design
We conducted this randomized, controlled, nonin-
feriority trial in eight Spanish regions (Aragón, 
Basque Country, Canarias, Catalonia, Galicia, Ma-
drid, Murcia, and Valencia) with the participation of 
15 tertiary care hospitals. The study was designed 
to assess the efficacy of one-time colonoscopy and 
biennial FIT for reducing the rate of death from 
colorectal cancer at 10 years (primary trial out-
come). The study started in November 2008 with an 
informative nationwide campaign.22 The recruit-
ment period was initiated in June 2009, and the first 
round finished in June 2011. Ten-year follow-up 
will be completed in 2021.
The study protocol (available with the full text 
of this article at NEJM.org) was approved by the 
ethics committee at each hospital, and all subjects 
provided written informed consent.
Study Population
Asymptomatic men and women between the ages 
of 50 and 69 years were eligible for enrollment. 
Exclusion criteria, which were ascertained after 
randomization by means of a questionnaire at the 
local screening office, included a personal history 
of colorectal cancer, adenoma, or inflammatory 
bowel disease; a family history of hereditary or 
familial colorectal cancer (i.e., ≥2 first-degree rel-
atives with colorectal cancer or 1 in whom the dis-
ease was diagnosed before the age of 60 years)23,24; 
a severe coexisting illness; and previous colecto-
my. Subjects were also temporarily excluded if 
they had undergone fecal occult blood testing in 
the previous 2 years or sigmoidoscopy or colo-
noscopy within the previous 5 years or if they 
had symptoms requiring additional workup. The 
subjects with previous screening tests became 
eligible when sufficient time had elapsed since 
the tests,2 and those with symptoms became eli-
gible if the results of the clinical workup were 
negative.
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Randomization
Subjects were identified through each Community 
Health Registry, sorted according to household, and 
stratified according to age (in 5-year age groups) 
and sex. Households were randomly assigned in a 
1:1 ratio to undergo either one-time colonoscopy 
or biennial FIT. Randomization was performed be-
fore invitation with the use of a computer-generated 
allocation algorithm on the basis of a randomized-
blocks method. Subjects were sent a preinvitation 
letter containing information on colorectal-cancer 
screening and the rationale for the study. Two 
weeks later, an invitation letter was sent indicating 
the subject’s study-group assignment. Two addi-
tional, reminder letters were mailed 3 and 6 months 
after the invitation to subjects who did not respond 
to the first mailed invitation. Subjects who agreed 
to participate in the study received an appointment 
at the local screening office, where they completed 
the questionnaire. The study design allowed for 
crossover between the two study groups.
Study Interventions
Among patients undergoing colonoscopy, bowel 
cleansing and sedation were performed as de-
scribed previously.25 All colonoscopies were per-
formed by experienced endoscopists (those who 
had performed >200 colonoscopies per year).26 Pol-
yps were categorized as non-neoplastic or neoplas-
tic. Adenomas measuring 10 mm or more in diam-
eter, with villous architecture, high-grade dysplasia, 
or intramucosal carcinoma, were classified as ad-
vanced adenomas. Invasive cancer was considered 
to be present when malignant cells were observed 
beyond the muscularis mucosae. Advanced neo-
plasm was defined as advanced adenoma or inva-
sive cancer. Tumor staging, performed according 
to the classification system of the American Joint 
Committee on Cancer,27 was based on the most 
advanced lesion.
The FIT strategy consisted of analysis of a single 
stool sample with the use of the automated semi-
quantitative OC-Sensor (Eiken Chemical) without 
specific restrictions on diet or medication use. 
Samples were processed as described previously28 
at each regional hospital. Subjects who were found 
to have a hemoglobin level of 75 ng per milliliter 
or more were invited to undergo colonoscopy.
Details regarding quality indicators for colonos-
copy are provided in the study protocol and in Ta-
ble 1 in the Supplementary Appendix, available at 
NEJM.org.
Study Oversight
Palex Medical and Biogen Diagnóstica donated sup-
plies and automated fecal occult-blood analyzers 
used for FIT but provided no other support for the 
study. The companies were not involved in the de-
sign of the study, in the analysis or interpretation of 
the data, or in the preparation of the manuscript.
Statistical Analysis
This study was based on the assumption that 
screening average-risk subjects by means of bien-
nial FIT would not be inferior to one-time colonos-
copy with respect to the rate of death from colorec-
tal cancer at 10 years. The calculations were based 
on an overall compliance rate of 30% and a crude 
10-year rate of death from colorectal cancer of 
6.96%.29 Therefore, assuming a crude 10-year rate 
of death from colorectal cancer of 1.74% among 
subjects undergoing colonoscopy (a 75% reduction) 
and of 3.41% among those screened by means of 
FIT (a 51% reduction) and accepting a noninferi-
ority condition if the absolute difference was below 
1.6 percentage points, we determined that a sample 
of 55,498 subjects (27,749 in each study group) 
would provide a power of 80%. A P value of less 
than 0.025 was considered to indicate statistical 
significance with the use of a one-sided test of 
proportions.30
We assessed study outcomes in both intention-
to-screen and as-screened analyses. In the latter 
analysis, the detection rate was calculated as the 
number of subjects with true positive results di-
vided by the number of subjects who actually un-
derwent testing. The diagnostic yield was the 
number of subjects with true positive results 
divided by the number of eligible subjects in the 
intention-to-screen analysis. Subjects were exclud-
ed from the intention-to-screen analysis if they at-
tended the screening office visit and met one or 
more exclusion criteria. Subjects who did not at-
tend the screening office visit and thus did not 
provide information about exclusion criteria were 
classified as eligible and were included in the 
intention-to-screen analysis. Definitions of other 
outcomes are provided in the study protocol. Be-
tween-group differences in rates of participation, 
diagnostic yield, detection, and complications were 
established by logistic-regression analysis, with 
adjustment for age, sex, and participating center, 
and are reported as odds ratios with 95% confi-
dence intervals. All analyses were performed with 
the use of SPSS statistical software, version 15.0.
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R esult s
Study Population
Overall, 57,404 subjects were randomly assigned to 
undergo either colonoscopy or FIT. Of these sub-
jects, 1970 could not be contacted and 2132 were 
excluded either permanently (1.7% in the colonos-
copy group and 1.3% in the FIT group, P = 0.20) or 
temporarily (2.2% in the colonoscopy group and 
2.2% in the FIT group, P = 0.11) (Fig. 1). The eligible 
population consisted of 26,703 subjects in the colo-
noscopy group and 26,599 in the FIT group. The 
two groups were almost identical regarding both 
mean (±SD) age (59.2±5.5 years in the colonoscopy 
group and 59.3±5.6 years in the FIT group, P = 0.35) 
and the proportion of subjects who were women 
(53.5% in the colonoscopy group and 54.3% in the 
FIT group, P = 0.25).
Participation
Among subjects who were assigned to undergo 
colonoscopy, 5649 subjects accepted the pro-
posed strategy, whereas 1706 requested to be 
screened by means of FIT (Fig. 1). Of the 5649 
subjects who agreed to undergo colonoscopy, 
4953 actually did so, and 1628 underwent FIT, for 
a participation rate of 24.6%, according to the 
intention-to-screen analysis (average age, 59.1±5.5 
years; proportion of subjects who were women, 
53.4%). Among subjects who were assigned to 
undergo FIT, 9353 subjects accepted the pro-
posed strategy, whereas 117 asked to be screened 
by colonoscopy. A total of 8983 subjects under-
went FIT, and 106 underwent colonoscopy, for an 
overall participation rate of 34.2% (average age, 
59.3±5.6 years; proportion of subjects who were 
women, 54.4%). Therefore, there were differenc-
es between study groups regarding both the rate 
of participation (odds ratio in the colonoscopy 
group, 0.63; 95% confidence interval [CI], 0.60 to 
0.65; P<0.001) and the crossover rate (odds ratio, 
16.8; 95% CI, 13.9 to 20.2; P<0.001).
Diagnostic Yield
In the intention-to-screen analysis, colorectal can-
cer was detected in 30 subjects (0.1%) in the colo-
noscopy group and in 33 subjects (0.1%) in the FIT 
group (odds ratio in the colonoscopy group, 0.99; 
95% CI, 0.61 to 1.64; P = 0.99) (Table 1). Advanced 
adenomas were found in 514 subjects (1.9%) in the 
colonoscopy group and in 231 subjects (0.9%) in 
the FIT group (odds ratio, 2.30; 95% CI, 1.97 to 
2.69; P<0.001). Nonadvanced adenomas were found 
in 1109 subjects (4.2%) in the colonoscopy group 
and in 119 subjects (0.4%) in the FIT group (odds 
ratio, 9.80; 95% CI, 8.10 to 11.85; P<0.001).
When the diagnostic yield was analyzed ac-
cording to the location of lesions, no significant 
between-group difference was found for either 
proximal or distal colorectal cancer (Table 2). 
However, colonoscopy performed significantly bet-
ter than FIT in the diagnosis of advanced and 
nonadvanced adenomas that were either proximal 
or distal to the splenic flexure. The superior diag-
nostic yield of colonoscopy for advanced adenomas 
was most evident for lesions in the proximal colon 
(Table 2).
Detection Rate
On the basis of the screening that was actually per-
formed, 5059 subjects underwent colonoscopy and 
10,611 underwent FIT (Fig. 1). Among subjects who 
were screened by means of FIT, 767 (7.2%) tested 
positive, and 663 of these subjects (86.4%) under-
went colonoscopy. Among subjects who were 
screened by means of colonoscopy, 27 (0.5%) were 
found to have colorectal cancer, as compared with 
36 subjects (0.3%) who were screened by means of 
FIT (odds ratio, 1.56; 95% CI, 0.93 to 2.56; P = 0.09) 
(Table 3). 
Tumor staging was similar in the two groups. 
In the FIT group, 24 tumors were stage I, 6 were 
stage II, and 6 were stage III. In the colonoscopy 
group, 19 tumors were stage I, 6 were stage II, and 
2 were stage III (P = 0.52). Colonoscopy was supe-
rior to FIT in the rates of detection of advanced 
adenomas (odds ratio, 4.32; 95% CI, 3.69 to 5.07; 
P<0.001) and nonadvanced adenomas (odds ratio, 
25.98; 95% CI, 21.27 to 31.74; P<0.001) (Table 3).
No significant difference was observed in the 
rate of detection of colorectal cancer when subjects 
were stratified according to tumor location (Table 
2 in the Supplementary Appendix). However, colo-
noscopy performed better than FIT with respect to 
detection rates for advanced and nonadvanced ad-
enomas in both the proximal and distal colon.
Analysis of Resources
The numbers of subjects who needed to be screened 
to find one colorectal cancer were 191 in the colo-
noscopy group and 281 in the FIT group, and the 
numbers who needed to be screened to find any 
advanced neoplasm were 10 and 36, respectively 
(Table 3 in the Supplementary Appendix). However, 
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57,404 Patients underwent randomization
28,708 Were assigned
to colonoscopy
28,696 Were assigned to FIT
916 Were not contacted 1054 Were not contacted
7368 Attended screening office 9512 Attended screening office
5649 Accepted colonoscopy
4953 Completed colonoscopy
92 Had positive results on FIT
76 Completed colonoscopy
675 Had positive results on FIT
587 Completed colonoscopy
Results:
4 CRC
32 Advanced adenomas
9 Nonadvanced adenomas
Results:
26 CRC
482 Advanced adenomas
1100 Nonadvanced adenomas
Results:
32 CRC
220 Advanced adenomas
103 Nonadvanced adenomas
Results:
1 CRC
11 Advanced adenomas
16 Nonadvanced adenomas
27,792 Were invited to undergo
colonoscopy
27,642 Were invited to undergo
FIT
472 Were permanently excluded
206 Had previous CRC or adenoma
56 Had inflammatory bowel disease
147 Had family history of CRC or polyposis
63 Had severe coexisting illness
617 Were temporarily excluded
60 Had colorectal symptoms
557 Had previous screening test
431 Were permanently excluded
170 Had previous CRC or adenoma
60 Had inflammatory bowel disease
177 Had family history of CRC or polyposis
24 Had severe coexisting illness
612 Were temporarily excluded
61 Had colorectal symptoms
551 Had previous screening test
26,703 Were eligible
for colonoscopy
26,599 Were eligible for FIT
117 Requested colonoscopy
106 Completed colonoscopy
1706 Requested FIT
1628 Completed FIT
9353 Accepted FIT
8983 Completed FIT
Figure 1. Enrollment and Outcomes.
A total of 1970 subjects were not contacted after being randomly assigned to undergo either colonoscopy or fecal immunochemical test-
ing (FIT) because they had died or had an inaccurate mailing address, which resulted in the return of the invitation letters. Criteria for 
permanent exclusion were a personal history of inflammatory bowel disease, colorectal polyps, or colorectal cancer (CRC) and a family 
history of CRC or polyposis syndromes. Temporary exclusion criteria were the presence of symptoms suggestive of colorectal disease 
and occult blood testing within the previous 2 years or sigmoidoscopy or colonoscopy within the previous 5 years. The subjects with pre-
vious screening tests became eligible when sufficient time had elapsed since the tests, and those with symptoms became eligible if the 
results of the clinical workup were negative.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSIDAD AUTONOMA DE MADRID RECTORADO on October 30, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 366;8 nejm.org february 23, 2012702
the numbers of subjects who needed to undergo 
colonoscopy to find one colorectal cancer were 
191 in the colonoscopy group and 18 in the FIT 
group; to find any advanced neoplasm, the num-
bers were 10 and 2, respectively (Table 3 in the 
Supplementary Appendix).
Complications
Major complications occurred in 24 subjects (0.5%) 
in the colonoscopy group (12 subjects with bleed-
ing, 10 subjects with hypotension or bradycardia, 
1 subject with perforation, and 1 subject with de-
saturation) and in 10 subjects (0.1%) in the FIT 
group (8 subjects with bleeding and 2 subjects with 
hypotension or bradycardia, all of whom required 
colonoscopy because of a positive result on FIT). 
Accordingly, the complication rate was higher in 
the colonoscopy group than in the FIT group (odds 
ratio, 4.81; 95% CI, 2.26 to 10.20; P<0.001).
Discussion
In this trial, participation rates were low in both 
groups of subjects who were invited to undergo 
colorectal-cancer screening, but subjects in the FIT 
group were more likely to agree to participate than 
those in the colonoscopy group. The number of pa-
tients in whom colorectal cancer was detected was 
similar in the two study groups, but more patients 
with adenomas were identified in the colonoscopy 
group. Since the primary outcome of this trial is the 
reduction in the rate of death from colorectal can-
cer at 10 years, the relative benefits and risks of the 
two strategies will be assessed at the end of the 
trial.
Our study has a number of strengths. We used 
a randomized design to compare a sensitive, semi-
quantitative FIT with colonoscopy. The study 
design accepts crossover between groups and in-
cludes intention-to-screen and as-screened anal-
yses.9 Our analyses incorporated stratification of 
results according to the location of detected le-
sions, thus allowing assessment of differences in 
procedure performance in both the proximal and 
distal colon, a critical issue that has become con-
troversial in recent years.31
However, the study also has a number of limi-
tations. First, the generalizability of the study 
findings is limited because participation in each 
screening strategy, a critical aspect with a direct 
effect on the diagnostic yield, depends on several 
factors and varies geographically. To overcome this 
limitation, we also evaluated the rate of detection 
of the screening procedure that was actually per-
formed in order to establish the intrinsic efficacy 
of both strategies. Second, although recruitment 
was encouraged, the rate of participation was 
lower than expected according to European pop-
ulation-based screening programs5 and American 
colonoscopy-based strategies.31 However, it is im-
portant to note that our participation rate did not 
differ from the corresponding rates in other trials 
that were performed in a similar setting.19,21
The most relevant result of this interim analysis 
Table 1. Diagnostic Yield of Colonoscopy and Fecal Immunochemical Testing (FIT), According to the Intention-to-Screen 
Analysis.*
Colorectal Lesion
Colonoscopy 
(N = 26,703)
FIT 
(N = 26,599)
Odds Ratio
(95% CI)† P Value
Subjects Rate Subjects Rate
no. % no. %
Cancer 30 0.1 33 0.1 0.99 (0.61–1.64) 0.99
Advanced adenoma‡ 514 1.9 231 0.9 2.30 (1.97–2.69) <0.001
Advanced neoplasia§ 544 2.0 264 1.0 2.14 (1.85–2.49) <0.001
Nonadvanced adenoma 1109 4.2 119 0.4 9.80 (8.10–11.85) <0.001
Any neoplasia 1653 6.2 383 1.4 4.67 (4.17–5.24) <0.001
* The diagnostic yield was calculated as the number of subjects with true positive results divided by the number of sub-
jects who were eligible to undergo testing. Subjects were classified according to the most advanced lesion. 
† Odds ratios were adjusted for age, sex, and participating center. CI denotes confidence interval.
‡ Advanced adenoma was defined as an adenoma measuring 10 mm or more in diameter, with villous architecture 
(>25%), high-grade dysplasia, or intramucosal carcinoma.
§ Advanced neoplasia was defined as advanced adenoma or cancer.
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is that one-time screening with FIT was very simi-
lar to one-time colonoscopy with respect to the rate 
of detection of colorectal cancer, and there was no 
significant difference in the stage of tumors de-
tected by the two strategies. Additional cases of 
colorectal cancer might be detected during ongo-
ing biennial FIT screening, and this could lead to 
an increased rate of cancer detection and a de-
creased rate of death in this group. On the other 
hand, more tumors might have been prevented in 
the colonoscopy group owing to the larger number 
of adenomas detected and removed, in comparison 
with the FIT group.
The higher detection rate and diagnostic yield 
of colonoscopy with respect to premalignant le-
sions also warrant comment. First, since advanced 
adenomas are usually considered a surrogate 
marker for colorectal cancer,32,33 the superiority of 
colonoscopy for detecting such lesions should be 
considered a potential advantage of this strategy in 
terms of reducing not only the rate of death from 
colorectal cancer but also the incidence of dis-
ease.34 However, this effect was diminished in our 
study by the lower participation rate in the colo-
noscopy group than in the FIT group. Moreover, 
the first round of FIT screening detected about half 
the number of advanced adenomas that were de-
tected by colonoscopy. The lower participation rate 
in the colonoscopy group and the recurrent nature 
of FIT screening may reduce the apparent advan-
tage of colonoscopy. On the other hand, the re-
markably high detection rate with colonoscopy for 
patients with nonadvanced adenomas is more dif-
ficult to interpret. Most of these lesions correspond 
to low-risk adenomas, with a natural history that 
is more unpredictable but unquestionably less 
prone to progression to colorectal cancer than the 
natural history of advanced adenoma.34,35 Indeed, 
Table 2. Diagnostic Yield of Colonoscopy and Fecal Immunochemical Testing (FIT), According to the Intention-to-Screen 
Analysis and the Location of the Colorectal Lesion.*
Colorectal Lesion
Colonoscopy
(N = 26,703)
FIT
(N = 26,599)
Odds Ratio
(95% CI)† P Value
Subjects Rate Subjects Rate
no. % no. %
Cancer
Proximal 6 <0.1 11 <0.1 0.56 (0.21–1.53) 0.26
Distal 25 0.1 23 0.1 1.22 (0.69–2.16) 0.49
Advanced adenoma‡
Proximal 199 0.7 51 0.2 4.06 (2.98–5.53) <0.001
Distal 365 1.4 206 0.8 1.82 (1.53–2.16) <0.001
Advanced neoplasia§
Proximal 205 0.8 62 0.2 3.44 (2.58–4.57) <0.001
Distal 390 1.5 229 0.9 1.76 (1.49–2.08) <0.001
Nonadvanced adenoma
Proximal 608 2.3 62 0.2 10.06 (7.74–13.08) <0.001
Distal 677 2.5 85 0.3 8.21 (6.55–10.29) <0.001
Any neoplasia
Proximal 813 3.0 124 0.5 6.84 (5.65–8.27) <0.001
Distal 1067 4.0 314 1.2 3.58 (3.15–4.07) <0.001
* The diagnostic yield was calculated as the number of subjects with true positive results divided by the number of sub-
jects who were eligible to undergo testing. Subjects were classified according to the most advanced lesion that was 
proximal or distal to the splenic flexure. The total number of subjects with proximal and distal lesions may exceed the 
total number of subjects because subjects could have lesions in both locations.
† Odds ratios were adjusted for age, sex, and participating center.
‡ Advanced adenoma was defined as an adenoma measuring 10 mm or more in diameter, with villous architecture 
(>25%), high-grade dysplasia, or intramucosal carcinoma.
§ Advanced neoplasia was defined as either advanced adenoma or cancer.
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recent European guidelines for quality assurance in 
colorectal-cancer screening consider patients with 
only one or two small adenomas (<10 mm in di-
ameter) to be at low risk and thus to be appropriate 
candidates for the same screening strategy that is 
recommended for patients without adenomas.36 
Accordingly, the lower rate of detection of these 
lesions among patients who underwent screening 
by means of FIT might be seen as an additional 
advantage of this strategy, since it would reduce 
the number of patients who would need to un-
dergo colonoscopy, with consequent reductions in 
costs and colonoscopy-related complications. This 
issue will be assessed at the end of the trial.
An interesting aspect of our study is the differ-
ential performance of screening strategies accord-
ing to the location of the neoplasm. This aspect of 
colorectal-cancer screening is controversial since it 
has been suggested that both colonoscopy and FIT 
are less effective for detecting lesions located in the 
proximal colon than in the distal colon.37 A case–
control study showed that colonoscopy was strong-
ly associated with a reduction in mortality from 
left-sided colorectal cancer but not from right-sided 
tumors.9 FIT seems to detect lesions that are 
mainly located distally to the splenic flexure.38 In 
this interim analysis, we observed no significant 
between-group difference in side-specific colorec-
tal-cancer detection, but more advanced and non-
advanced adenomas in both the proximal and 
distal colon were detected in the colonoscopy 
group than in the FIT group. This difference was 
significantly higher for advanced adenomas in the 
proximal colon than in the distal colon. Precise 
explanations for these differential findings or how 
they may influence long-term results are unclear.
In summary, in this interim analysis, subjects 
in the FIT group were more likely to participate in 
colorectal-cancer screening than subjects in the 
colonoscopy group. On the baseline screening ex-
amination, the number of subjects in whom 
colorectal cancer was detected was similar in the 
two study groups, but more adenomas were de-
tected in the colonoscopy group. The comparative 
effectiveness of FIT and colonoscopy for preventing 
death from colorectal cancer will be assessed at the 
completion of this 10-year trial.
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Table 3. Detection Rate for Colonoscopy and Fecal Immunochemical Testing (FIT), According to the As-Screened 
Analysis.*
Colorectal Lesion
Colonoscopy
(N = 5059)
FIT
(N = 10,507)†
Odds Ratio 
(95% CI)‡ P Value
Subjects Rate Subjects Rate
no. % no. %
Cancer 27 0.5 36 0.3 1.56 (0.93–2.56) 0.09
Advanced adenoma§ 493 9.7 252 2.4 4.32 (3.69–5.07) <0.001
Advanced neoplasia¶ 520 10.3 288 2.7 4.01 (3.45–4.67) <0.001
Nonadvanced adenoma 1116 22.1 112 1.1 25.98 (21.27–31.74) <0.001
Any neoplasia 1636 32.3 400 3.8 12.28 (10.89–13.84) <0.001
* The detection rate is the comparison between the number of positive results and the number of subjects who actually 
underwent testing. Subjects were classified according to the most advanced lesion. 
† A total of 104 subjects with positive results on FIT did not undergo colonoscopy.
‡ Odds ratios were adjusted according to age, sex, and participating center.
§ Advanced adenoma was defined as an adenoma measuring 10 mm or more in diameter, with villous architecture 
(>25%), high-grade dysplasia, or intramucosal carcinoma.
¶ Advanced neoplasia was defined as advanced adenoma or cancer.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSIDAD AUTONOMA DE MADRID RECTORADO on October 30, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Colonoscopy vs. Fecal Immunochemical Testing
n engl j med 366;8 nejm.org february 23, 2012 705
Appendix
The authors’ affiliations are as follows: the Department of Gastroenterology, Hospital Universitario de Canarias, Tenerife (E.Q., I.A.-A.); 
the Department of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas 
(CIBERehd), Institut d’Ivestigacions Biomediques August Pi i Sunyer (A.C.), the Department of Gastroenterology, Parc de Salut Mar, 
Institut Municipal d’Investigació Mèdica (IMIM), Pompeu Fabra University (M. Andreu, X.B., O.F.-A.), the Department of Epidemiology 
and Evaluation, Parc de Salut Mar, IMIM (C.H.), and Unitat d’Avaluació, Suport i Preventiva, Hospital Clínic (J.G., A.S.) — all in Barcelona; 
the Department of Gastroenterology, Donostia Hospital, CIBERehd, University of Basque Country (L.B.), the Department of Gastroen-
terology, Instituto Oncológico, Obra Social Kutxa (I.M.), and the Department of Gastroenterology, Policlinica Gipuzkoa, CIBERehd 
(J.A.) — all in San Sebastián; the Department of Gastroenterology, Complexo Hospitalario Universitario de Ourense, Ourense (J.C., 
E.C.); the Colorectal Cancer Screening Program, Dirección General de Salud Pública, Conselleria de Sanitat (D.S., T.S., M. Andres, 
G.T.), and the Department of Gastroenterology, Hospital Universitario La Fe (M.P.) — both in Valencia; the Department of Gastroen-
terology, University of Zaragoza, IIS Aragón, CIBERehd, Zaragoza (A.L., M.-P.R., M.P.-T.); Unidad de Gestión Clínica de Digestivo, 
Hospital Universitario Virgen de la Arrixaca (F.C., A.O.), the Colorectal Cancer Prevention Program of the Región de Murcia, Servicio 
Murciano de Salud (J.C.), and the Colorectal Cancer Prevention Program of the Región de Murcia, Dirección General de Salud Pública, 
Consejería de Sanidad y Política Social (F.P.-R.) — all in Murcia; the Department of Gastroenterology, Hospital Clínico San Carlos 
(J.D.M., C.P.), the Department of Gastroenterology, Hospital Fundación Alcorcón (G.C.), the Department of Gastroenterology, Hospital 
12 de Octubre (J.D.-T.), the Department of Gastroenterology, Hospital de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), 
and CIBERehd (C.S.), and the Regional Office for Oncology Coordination, Consejería de Sanidad (A.G.-N.) — all in Madrid; the Gas-
troenterology Unit, Hospital General Universitario de Alicante, Alicante (R.J.); the Department of Gastroenterology, Lasarte-Oria Health 
Center, Osakidetza-Basque Health Service, Guipúzcoa (E.L.); the Department of Gastroenterology, Complexo Hospitalario Universitario 
de Vigo, Vigo (V.H., F.I.); Dirección Xeral de Innovación e Xestión da Saúde Pública, Conselleria de Sanidade, Xunta de Galicia (R.Z.); 
the Department of Gastroenterology, Consorcio Hospitalario de Castellón, Castellón (A.P.); the Colorectal Cancer Screening Program 
of the Comunidad de Canarias, Servicio Canario de la Salud (M.V.-P., J.M.R.-M.); and the Department of Gastroenterology, Hospital 
Puerta de Hierro, Majadahonda (A.H.-T.) — all in Spain.
References
1. Ferlay J, Shin HR, Bray F, Forman D, 
Mathers C, Parkin DM. Estimates of world-
wide burden of cancer in 2008: GLOBOCAN 
2008. Int J Cancer 2010;127:2893-917.
2. Levin B, Lieberman DA, McFarland B, 
et al. Screening and surveillance for the 
early detection of colorectal cancer and 
adenomatous polyps, 2008: a joint guide-
line from the American Cancer Society, the 
US Multi-Society Task Force on Colorectal 
Cancer, and the American College of Radi-
ology. Gastroenterology 2008;134:1570-95.
3. Mandel JS, Church TR, Bond JH, et al. 
The effect of fecal occult-blood screening 
on the incidence of colorectal cancer. 
N Engl J Med 2000;343:1603-7.
4. Hewitson P, Glasziou P, Watson E, 
Towler B, Irwig L. Cochrane systematic 
review of colorectal cancer screening us-
ing the fecal occult blood test (Hemoc-
cult): an update. Am J Gastroenterol 2008; 
103:1541-9.
5. Atkin WS, Edwards R, Kralj-Hans I, et 
al. Once-only flexible sigmoidoscopy 
screening in prevention of colorectal can-
cer: a multicentre randomised controlled 
trial. Lancet 2010;375:1624-33.
6. Heitman SJ, Hilsden RJ, Au F, Dowden 
S, Manns BJ. Colorectal cancer screening 
for average-risk North Americans: an eco-
nomic evaluation. PLoS Med 2010;7(11): 
1000370.
7. Brenner H, Chang-Claude J, Seiler 
CM, Rickert A, Hoffmeister M. Protection 
from colorectal cancer after colonoscopy: 
a population-based, case-control study. 
Ann Intern Med 2011;154:22-30.
8. Brenner H, Haug U, Arndt V, Stegma-
ier C, Altenhofen L, Hoffmeister M. Low 
risk of colorectal cancer and advanced ad-
enomas more than 10 years after negative 
colonoscopy. Gastroenterology 2010;138: 
870-6.
9. Baxter NN, Goldwasser MA, Paszat 
LF, Saskin R, Urbach DR, Rabeneck L. As-
sociation of colonoscopy and death from 
colorectal cancer. Ann Intern Med 2009; 
150:1-8.
10. Brenner H, Chang-Claude J, Seiler 
CM, Hoffmeister M. Long-term risk of 
colorectal cancer after negative colonos-
copy. J Clin Oncol 2011;29:3761-7.
11. Imperiale TF, Glowinski EA, Lin-
Cooper C, Larkin GN, Rogge JD, Ransohoff 
DF. Five-year risk of colorectal neoplasia 
after negative screening colonoscopy. 
N Engl J Med 2008;359:1218-24. [Erratum, 
N Engl J Med 2009;361:2004.]
12. Kahi CJ, Imperiale TF, Juliar BE, Rex 
DK. Effect of screening colonoscopy on 
colorectal cancer incidence and mortality. 
Clin Gastroenterol Hepatol 2009;7:770-5, 
quiz 711.
13. Citarda F, Tomaselli G, Capocaccia R, 
Barcherini S, Crespi M. Efficacy in stan-
dard clinical practice of colonoscopic pol-
ypectomy in reducing colorectal cancer 
incidence. Gut 2001;48:812-5.
14. Winawer SJ, Zauber AG, Ho MN, et al. 
Prevention of colorectal cancer by colono-
scopic polypectomy. N Engl J Med 1993; 
329:1977-81.
15. Dancourt V, Lejeune C, Lepage C, 
Gailliard MC, Meny B, Faivre J. Immuno-
chemical faecal occult blood tests are su-
perior to guaiac-based tests for the detec-
tion of colorectal neoplasms. Eur J Cancer 
2008;44:2254-8.
16. Hol L, Wilschut JA, van Ballegooijen 
M, et al. Screening for colorectal cancer: 
random comparison of guaiac and immu-
nochemical faecal occult blood testing at 
different cut-off levels. Br J Cancer 2009; 
100:1103-10.
17. Parra-Blanco A, Gimeno-García AZ, 
Quintero E, et al. Diagnostic accuracy of 
immunochemical versus guaiac faecal oc-
cult blood tests for colorectal cancer 
screening. J Gastroenterol 2010;45:703-12.
18. van Rossum LG, van Rijn AF, Laheij 
RJ, et al. Random comparison of guaiac 
and immunochemical fecal occult blood 
tests for colorectal cancer in a screening 
population. Gastroenterology 2008;135: 
82-90.
19. Levi Z, Birkenfeld S, Vilkin A, et al. A 
higher detection rate for colorectal cancer 
and advanced adenomatous polyp for 
screening with immunochemical fecal 
occult blood test than guaiac fecal occult 
blood test, despite lower compliance rate: 
a prospective, controlled, feasibility study. 
Int J Cancer 2011;128:2415-24.
20. Hol L, van Leerdam ME, van Balle-
gooijen M, et al. Screening for colorectal 
cancer: randomised trial comparing guaiac-
based and immunochemical faecal occult 
blood testing and flexible sigmoidoscopy. 
Gut 2010;59:62-8.
21. Segnan N, Senore C, Andreoni B, et 
al. Comparing attendance and detection 
rate of colonoscopy with sigmoidoscopy 
and FIT for colorectal cancer screening. 
Gastroenterology 2007;132:2304-12.
22. Andreu García M, Marzo M, Mascort 
J, et al.  Prevention of colorectal cancer. 
Gastroenterol Hepatol 2009;32:137-9. (In 
Spanish.)
23. Castells A, Castellví-Bel S, Balaguer F. 
Concepts in familial colorectal cancer: 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSIDAD AUTONOMA DE MADRID RECTORADO on October 30, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
n engl j med 366;8 nejm.org february 23, 2012706
Colonoscopy vs. Fecal Immunochemical Testing
where do we stand and what is the future? 
Gastroenterology 2009;137:404-9.
24. Piñol V, Castells A, Andreu M, et al. 
Accuracy of revised Bethesda guidelines, 
microsatellite instability, and immuno-
histochemistry for the identification of 
patients with hereditary nonpolyposis 
colorectal cancer. JAMA 2005;293:1986-94.
25. Parra-Blanco A, Nicolas-Perez D, Gi-
meno-Garcia A, et al. The timing of bowel 
preparation before colonoscopy deter-
mines the quality of cleansing, and is a 
significant factor contributing to the de-
tection of flat lesions: a randomized study. 
World J Gastroenterol 2006;12:6161-6.
26. Guía de práctica clínica de calidad en 
la colonoscopia de cribado del cáncer color-
rectal. Asociación Española de Gastroen-
terología y Sociedad Española de Endo-
scopia Digestiva, 2011 (http://www.aegastro 
.es/docs/cribado_colon.pdf).
27. O’Connell JB, Maggard MA, Ko CY. 
Colon cancer survival rates with the new 
American Joint Committee on Cancer 
sixth edition staging. J Natl Cancer Inst 
2004;96:1420-5.
28. Vilkin A, Rozen P, Levi Z, et al. Perfor-
mance characteristics and evaluation of 
an automated-developed and quantitative, 
immunochemical, fecal occult blood 
screening test. Am J Gastroenterol 2005; 
100:2519-25.
29. Scholefield JH, Moss SM. Faecal oc-
cult blood screening for colorectal cancer. 
J Med Screen 2002;9:54-5.
30. Hollis S, Campbell F. What is meant 
by intention to treat analysis? Survey of 
published randomised controlled trials. 
BMJ 1999;319:670-4.
31. Lieberman D. A call to action — mea-
suring the quality of colonoscopy. N Engl 
J Med 2006;355:2588-9.
32. Arber N, Eagle CJ, Spicak J, et al. Cele-
coxib for the prevention of colorectal ad-
enomatous polyps. N Engl J Med 2006; 
355:885-95.
33. Baron JA, Cole BF, Sandler RS, et al. A 
randomized trial of aspirin to prevent 
colorectal adenomas. N Engl J Med 2003; 
348:891-9.
34. Lieberman DA, Weiss DG, Bond JH, 
Ahnen DJ, Garewal H, Chejfec G. Use of 
colonoscopy to screen asymptomatic adults 
for colorectal cancer. N Engl J Med 2000; 
343:162-8. [Erratum, N Engl J Med 2000; 
343:1204.]
35. Lieberman DA, Weiss DG, Harford WV, 
et al. Five-year colon surveillance after 
screening colonoscopy. Gastroenterology 
2007;133:1077-85.
36. European guidelines for quality as-
surance in colorectal cancer screening and 
diagnosis. Brussels: European Commis-
sion, 2011 (http://bookshop.europa.eu/ 
is-bin/INTERSHOP.enfinity/WFS/ 
EU-Bookshop-Site/en_GB/-/EUR/ 
ViewPublication-Start?PublicationKey=
ND3210390).
37. Lieberman D. Colon cancer screening 
and surveillance controversies. Curr Opin 
Gastroenterol 2009;25:422-7.
38. Haug U, Kuntz KM, Knudsen AB, 
Hundt S, Brenner H. Sensitivity of immu-
nochemical faecal occult blood testing for 
detecting left- vs right-sided colorectal 
neoplasia. Br J Cancer 2011;104:1779-85.
Copyright © 2012 Massachusetts Medical Society.
an nejm app for iphone
The NEJM Image Challenge app brings a popular online feature to the smartphone. 
Optimized for viewing on the iPhone and iPod Touch, the Image Challenge app lets 
you test your diagnostic skills anytime, anywhere. The Image Challenge app 
randomly selects from 300 challenging clinical photos published in NEJM,  
with a new image added each week. View an image, choose your answer,  
get immediate feedback, and see how others answered.  
The Image Challenge app is available at the iTunes App Store.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSIDAD AUTONOMA DE MADRID RECTORADO on October 30, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
